$BMY Recent News 4 stocks to watch 1:44 p.m. Nov. 19,

New Post Public Reply Private Reply Replies (0) Message Board

Dec 7, 2014 at 9:47 AM

$BMY Recent News

4 stocks to watch 1:44 p.m. Nov. 19, 2014 - The Trading Deck
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Charting a bullish post-election backdrop 11:05 a.m. Nov. 5, 2014 - Michael Ashbaugh
6 stocks to watch 1:35 p.m. Oct. 29, 2014 - The Trading Deck
Updates, advisories and surprises 11:31 a.m. Oct. 24, 2014 - MarketWatch
Amazon, Pandora sink in wake of results; KLA-Tencor surges 9:49 a.m. Oct. 24, 2014 - Sue Chang
Bristol-Myers profit slips, but tops expectations 6:45 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers sees 2014 total sales $15.2 bln-$15.8 bln vs. FactSet consensus $15.58 bln 6:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers lowers 2014 net EPS outlook to $1.15-$1.25 from $1.50-$1.60 6:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers affirms 2014 adj. EPS outlook of $1.70-$1.80 6:34 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 FactSet sales consensus $3.81 bln 6:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 sales $3.92 bln vs. $4.07 bln a year ago 6:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 adj. EPS 45 cents vs. FactSet consensus 42 cents 6:32 a.m. Oct. 24, 2014 - Tomi Kilgore
Mead Johnson Nutrition profit rises 9.5% 7:21 a.m. Oct. 23, 2014 - MarketWatch.com
More than 1/3 of Dow stocks to report this week 4:31 a.m. Oct. 19, 2014 - Wallace Witkowski
Bristol-Myers drops Hepatitis C dual regimen in U.S. 10:15 a.m. Oct. 7, 2014 - Jonathan D. Rockoff
FDA approves Merck's new-kind of cancer drug 1:58 p.m. Sept. 4, 2014 - MarketWatch.com
5 companies that will benefit from ALS awareness 6:58 a.m. Aug. 22, 2014 - Jennifer Booton
Glaxo chief faces increasing pressure: WSJ 5:29 p.m. Aug. 11, 2014 - MarketWatch.com
Bristol-Myers adjusted profit beats expectations 7:24 a.m. July 24, 2014 - MarketWatch.com

InsiderInsights.com Daily Round Up 12/5/14: HEES, CCC, CUDA, SC 3:27 a.m. Today - Seeking Alpha
Two Cancer Drugs Shown Effective 1:09 p.m. Dec. 6, 2014 - The Wall Street Journal Interactive Edition
Merck, Bristol Immunotherapies Expand Strongly Into Blood Cancers 1:00 p.m. Dec. 6, 2014 - TheStreet.com
Seattle Genetics Makes Case for Expanded Use of Adcetris as Lymphoma Maintenance Therapy 11:00 a.m. Dec. 6, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks 8:31 p.m. Dec. 4, 2014 - TheStreet.com
Can Albert Einstein's Math Get You To The Finish Line? Retirement Portfolio Quarterly Review 3:57 p.m. Dec. 4, 2014 - Seeking Alpha
Cancer’s Super-Survivors 1:46 p.m. Dec. 4, 2014 - The Wall Street Journal Interactive Edition
Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14) 6:04 a.m. Dec. 4, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Cyclical Stocks Are Fund Manager Picks Now 8:36 p.m. Dec. 3, 2014 - TheStreet.com
Avanir Stock Jumps On $3.5 Billion Otsuka Buyout 10:22 a.m. Dec. 2, 2014 - Investors Business Daily
Retirement Portfolio For Dummies - The Health Care Components 1:42 p.m. Nov. 30, 2014 - Seeking Alpha
Vargatef cleared in Europe for lung cancer 9:23 a.m. Nov. 28, 2014 - Seeking Alpha
FDA Seeks More Data on Bristol-Myers Hepatitis C Therapy 12:17 p.m. Nov. 26, 2014 - The Wall Street Journal Interactive Edition
Bristol-Myers gets CRL for daclatasvir NDA 11:51 a.m. Nov. 26, 2014 - Seeking Alpha
December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey 6:00 a.m. Nov. 26, 2014 - TheStreet.com
Drug makers face pushback on pricey meds 8:18 a.m. Nov. 25, 2014 - Seeking Alpha
Bristol-Myers and Five Prime team up in cancer 9:29 a.m. Nov. 24, 2014 - Seeking Alpha
Pfizer/Merck KGaA Immune Checkpoint Deal Bodes Extremely Well For Compugen 12:21 p.m. Nov. 21, 2014 - Seeking Alpha
European Ad Comm gives thumbs up to AbbVie's HCV combo 8:48 a.m. Nov. 21, 2014 - Seeking Alpha
3 Best Vanguard Funds With Active Management 5:30 a.m. Nov. 21, 2014 - InvestorPlace.com

Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma 1:00 p.m. Dec. 6, 2014 - BusinessWire - BZX
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Bristol-Myers Squibb Foundation Marks World AIDS Day by Awarding $1.47 Millionin New Grants to Strengthen HIV-Related Services in Five Sub-Saharan Countries 9:01 a.m. Dec. 1, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C 11:34 a.m. Nov. 26, 2014 - BusinessWire - BZX
Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 8:24 p.m. Nov. 24, 2014 - PR Newswire - PRF
Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types 8:59 a.m. Nov. 24, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types 8:59 a.m. Nov. 24, 2014 - GlobeNewswire
Analyses from Phase IIIb Study Provide Additional Data in Earlier Use of Orencia (abatacept) Plus Methotrexate (MTX) in Citrullinated Protein (CCP)-Positive Adult Patients with Early Rheumatoid Arthritis (RA) 8:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial 3:45 a.m. Nov. 16, 2014 - BusinessWire - BZX
Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014 Annual Meeting 8:36 a.m. Nov. 12, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Foundation Awards $2 Million in New Grantsto Help Veterans and their Families Transition from Military to Civilian Life 9:00 a.m. Nov. 10, 2014 - BusinessWire - BZX
Upcoming Conferences, Contract Award, Quarterly Financial Results, and Completion of Acquisition - Research Reports on Bristol-Myers Squibb, 3M, Colony Financial, NOV and PPG 8:40 a.m. Nov. 10, 2014 - PR Newswire - PRF
ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients 9:00 a.m. Nov. 8, 2014 - BusinessWire - BZX
Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis 9:00 a.m. Nov. 8, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Receives the LEAD Award from The US Oncology Network 10:33 a.m. Nov. 7, 2014 - BusinessWire - BZX
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries 8:50 a.m. Nov. 6, 2014 - PR Newswire - PRF
Protagonist Therapeutics Elects Chaitan Khosla, Ph.D. to Board of Directors 8:35 a.m. Nov. 5, 2014 - PR Newswire - PRF
Lexicon Strengthens Clincial Operations And Commercial Readiness 4:15 p.m. Nov. 4, 2014 - PR Newswire - PRF
Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference 10:00 a.m. Nov. 4, 2014 - BusinessWire - BZX
Insider Trading Research for Micron, Bristol-Myers Squibb, Twitter, American Realty Capital Properties, Plug Power, and GoPro 8:45 a.m. Nov. 3, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Patented Foodservice Firm's $1.6M Sale: High ROI Potential

Cooking Up High Margins and Rapid Growth You don’t stumble on opportunities like this every day. A foodservice company out there is posting some mouth-watering numbers, and it’s shaking up the M&A scene. This one’s got patents holding up its brand like a culinary force field, and it’s now on the auction block for a cool $1.6 million. And the numbers? Well, they...

ATTACK SHARK Partners with Cloud9 League Team

Shaking Hands with Cloud9 ATTACK SHARK is jumping headfirst into the esports game, teaming up with Cloud9's League of Legends team. Now, before you roll your eyes at another corporate matchmaking play, consider the magic at play here. League of Legends isn't just any game; it's a titan in the esports universe, and partnering with Cloud9 offers a serious boost. It's not...

Hims & Hers Faces Legal Storm Over Alleged Privacy Breaches

Legal Storms Brew Over Alleged Privacy Breaches Well, here we go again, folks. Just when you think the waters are calming, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself in the thick of a nasty securities fraud class action lawsuit. Allegedly they've been less than honest with their customers' health info—something about sneaking around with people's sensitive data...

LG's High-Purity RGB Displays Shine at IFA 2026

LG's Latest Dazzler: RGB Evo Takes the Spotlight LG has never been shy about setting standards in the home entertainment sector, and they’re doing it again at IFA 2026 with their high-purity RGB displays. Make no mistake, when LG rolls out a massive LCD TV certified by TÜV Rheinland for color purity, every other home theater manufacturer is scrambling to keep up. "LG...

China Hour Expands Chinese Media Footprint in Africa

An Ambitious Cross-Continental Media Play The airwaves are getting a new twist. This time, it's a blend of cultures, as China Hour makes an entrance in South Africa. That's right, folks—Jiangsu Broadcasting Corporation (JSBC) has set up camp alongside the South African Broadcasting Corporation (SABC), pushing a big media wave across the continent. If you've been...

Auto Maintenance: Key Tips for Long-Term Vehicle Health

Beating Breakdown Blues: Preventative Maintenance Insights You ever look under the hood and wonder what's ticking away? Cars ain't just about turning keys and hitting gas—there's a beating heart under all that metal and rubber. That's what HelloNation's serving us here, with David Mantz and his kid, David Mantz Jr., lifting the lid on preventative maintenance. These...

Ice-Rock Avalanches: Future Risks and Urgent Lessons

Mounting Threats in Mountain Chains That nightmare on August 26 at Mount Langtang Lirung in Nepal—where an ice-rock avalanche triggered a catastrophic mudslide—brought a harsh reminder that these mountains are cracking wide open. With 31 dead and over 500 souls still unaccounted for, it's a chilling warning about how vulnerable high-altitude regions have become. A...

Nocpix's Evolution: New Thermal Riflescope Unveiled

Raising the Thermal Image Bar When Nocpix, known for cutting-edge electro-optical tech, teases a new thermal riflescope, it's time for hunters to perk up. This ain't just another gadget. We're talking about equipment that elevates precision and brings an edge to the field. Scheduled for hunters who mean business, this next-gen scope is destined to redefine what it means...

LiberNovo Demos Ergonomic Seating at IFA 2026

Riding the Ergonomic Wave at IFA 2026 No stranger to the innovation spotlight, LiberNovo’s got its eyes on Berlin this time around. As sparks fly at the IFA 2026, they’re rolling out their grand Maxis Series and rubbing shoulders with big names in technology. How does a company shake things up in a sea of tech? Start by thinking big and tall—literally. Maxis Series:...

Dreame Unveils Vast AI Product Range at IFA 2026

Overnight Sensation or Future Staple? I wonder if Dreame's top brass woke up sweating or smiling after their big reveal at IFA 2026. A buffet of over 100 products across 16 categories is no small feat, especially when you're banking on technologies developed over nine years. But let's cut through the noise—does this showcase promise innovation or just smoke and mirrors?...